Millipore Strengthens Bioprocess Division with Serologicals Acquistion
Millipore Corporation (Billerica, MA, www.millipore.com) and Serologicals Corporation (Norcross, GA, www.serologicals.com) have announced an agreement in which Millipore will acquire Serologicals in a cash transaction valued at approximately $1.4 billion and set to close by June 30, 2006.
Millipore Corporation (Billerica, MA, www.millipore.com) and Serologicals Corporation (Norcross, GA, www.serologicals.com) have announced an agreement in which Millipore will acquire Serologicals in a cash transaction valued at approximately $1.4 billion. The deal is set to close by June 30, 2006.
The agreement strengthens Millipore’s workforce to 5800 employees and builds its projected combined annual revenue to $1.4 billion.
Serologicals provides biological products, technologies, and services and maintains operations in both bioprocessing and research. The acquisition will boost Millipore’s Bioprocess Division in various growth segments, including drug discovery, antibodies, cell biology reagents, and stem cell research. The company also gains a cell-culture supplements offering, thereby facilitating entry into the $1-billion upstream bioprocessing market. The move reportedly makes Millipore the only company in the life sciences industry with both upstream cell-culture and downstream separation offerings for biopharmaceutical production.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
